Payment overview · 2025
General Payments
$1,687.16
67 reported records · 20 companies
Healthcare provider profile · identity verified
Tsovinar Tekkelian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · GLENDALE, CA · NPI 1558447607
Verified facts
What the public records show
CMS Open Payments records show Tsovinar Tekkelian, M.D. received $1,687.16 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Ubrelvy, Viberzi, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 861 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Viibryd by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 546 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $227.90 | 13.5% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $226.54 | 13.4% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.89 | 12.4% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $122.34 | 7.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.28 | 6.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.31 | 6.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $101.41 | 6.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.35 | 5.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.92 | 3.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.47 | 3.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.32 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.05 | 3.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.30 | 2.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.15 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.65 | 2.3% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $28.61 | 1.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $28.13 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.55 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.36 | 1.4% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $22.63 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,687.16 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $226.54 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $149.71 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $122.34 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $117.19 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $114.28 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.31 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $101.45 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $93.35 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $91.70 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $91.36 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $79.02 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $71.11 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $62.47 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.34 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.15 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 522 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 332 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 319 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 861 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 236 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 546 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 95 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIBERZI viberzi |
2025 | Viberzi | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
522 | 89 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
861 | 115 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
163 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
73 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
111 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
106 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
236 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
546 | 83 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
332 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
95 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 3923 | 510 |
| Gabapentin | Gabapentin | 3336 | 406 |
| Metoprolol Succinate | Metoprolol Succinate | 2501 | 323 |
| Amlodipine Besylate | Amlodipine Besylate | 1969 | 257 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1679 | 205 |
| Vascepa | Icosapent Ethyl | 1547 | 210 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 1438 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1362 | 160 |
| Clonidine Hcl | Clonidine Hcl | 1303 | 167 |
| Hydralazine Hcl | Hydralazine Hcl | 1260 | 149 |
| Furosemide | Furosemide | 1237 | 161 |
| Baclofen | Baclofen | 1200 | 163 |
| Diclofenac Sodium | Diclofenac Sodium | 1138 | 194 |
| Ibuprofen | Ibuprofen | 1048 | 176 |
| Omeprazole | Omeprazole | 1048 | 151 |
| Meclizine Hcl | Meclizine Hcl | 1013 | 159 |
| Lorazepam | Lorazepam | 998 | 154 |
| Losartan Potassium | Losartan Potassium | 981 | 137 |
| Memantine Hcl | Memantine Hcl | 947 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 921 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 888 | 128 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 883 | 103 |
| Linzess | Linaclotide | 861 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 820 | 127 |
| Meloxicam | Meloxicam | 790 | 123 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 788 | 127 |
| Icosapent Ethyl | Icosapent Ethyl | 787 | 174 |
| Metformin Hcl | Metformin Hcl | 779 | 113 |
| Trazodone Hcl | Trazodone Hcl | 770 | 99 |
| Dexlansoprazole Dr | Dexlansoprazole | 756 | 102 |
| Celecoxib | Celecoxib | 755 | 96 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 743 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 701 | 105 |
| Memantine Hcl Er | Memantine Hcl | 675 | 82 |
| Montelukast Sodium | Montelukast Sodium | 672 | 82 |
| Tramadol Hcl | Tramadol Hcl | 641 | 99 |
| Azithromycin | Azithromycin | 636 | 334 |
| Potassium Chloride | Potassium Chloride | 623 | 76 |
| Carvedilol | Carvedilol | 605 | 67 |
| Myrbetriq | Mirabegron | 594 | 80 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 589 | 100 |
| Fluticasone Propionate | Fluticasone Propionate | 575 | 93 |
| Glimepiride | Glimepiride | 557 | 56 |
| Alprazolam | Alprazolam | 549 | 68 |
| Ozempic | Semaglutide | 546 | 83 |
| Dicyclomine Hcl | Dicyclomine Hcl | 542 | 108 |
| Donepezil Hcl | Donepezil Hcl | 538 | 59 |
| Creon | Lipase/Protease/Amylase | 522 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 513 | 66 |
| Ezetimibe | Ezetimibe | 506 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 466 | 69 |
| Naproxen | Naproxen | 453 | 73 |
| Ventolin Hfa | Albuterol Sulfate | 444 | 72 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 440 | 75 |
| Famotidine | Famotidine | 439 | 63 |
| Atenolol | Atenolol | 415 | 50 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 402 | 80 |
| Alendronate Sodium | Alendronate Sodium | 402 | 45 |
| Ketoconazole | Ketoconazole | 396 | 59 |
| Sertraline Hcl | Sertraline Hcl | 394 | 46 |
| Simvastatin | Simvastatin | 386 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 378 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 378 | 64 |
| Glipizide | Glipizide | 365 | 43 |
| Lidocaine | Lidocaine | 358 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 341 | 50 |
| Eliquis | Apixaban | 332 | 43 |
| Allopurinol | Allopurinol | 328 | 43 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 327 | 40 |
| Jardiance | Empagliflozin | 319 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 315 | 38 |
| Nitroglycerin | Nitroglycerin | 307 | 47 |
| Colchicine | Colchicine | 295 | 35 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 289 | 32 |
| Nifedipine Er | Nifedipine | 287 | 34 |
| Diclofenac Potassium | Diclofenac Potassium | 285 | 47 |
| Sumatriptan Succinate | Sumatriptan Succinate | 276 | 33 |
| Clonidine | Clonidine | 273 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 56 |
| Fenofibrate | Fenofibrate Nanocrystallized | 269 | 41 |
| Januvia | Sitagliptin Phosphate | 269 | 35 |
| Clobetasol Propionate | Clobetasol Propionate | 260 | 44 |
| Valsartan | Valsartan | 257 | 32 |
| Fenofibrate | Fenofibrate | 250 | 33 |
| Clonazepam | Clonazepam | 244 | 28 |
| Repatha Sureclick | Evolocumab | 242 | 34 |
| Mounjaro | Tirzepatide | 236 | 44 |
| Ondansetron Odt | Ondansetron | 211 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 209 | 36 |
| Lisinopril | Lisinopril | 205 | 31 |
| Metformin Er Gastric | Metformin Hcl | 204 | 26 |
| Mirtazapine | Mirtazapine | 203 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 199 | 35 |
| Jentadueto | Linagliptin/Metformin Hcl | 198 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 196 | 25 |
| Diflorasone Diacetate | Diflorasone Diacetate | 195 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 194 | 33 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 192 | 39 |
| Mometasone Furoate | Mometasone Furoate | 192 | 33 |
| Tradjenta | Linagliptin | 188 | 22 |
| Hydrocortisone | Hydrocortisone | 185 | 37 |
| Meloxicam | Meloxicam, Submicronized | 179 | 19 |
| Finasteride | Finasteride | 178 | 19 |
| Prednisone | Prednisone | 169 | 80 |
| Clotrimazole | Clotrimazole | 164 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 164 | 21 |
| Zenpep | Lipase/Protease/Amylase | 163 | 27 |
| Fluocinonide | Fluocinonide | 155 | 24 |
| Xarelto | Rivaroxaban | 154 | 20 |
| Megestrol Acetate | Megestrol Acetate | 152 | 25 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 146 | 35 |
| Procto-Med Hc | Hydrocortisone | 145 | 25 |
| Azelastine Hcl | Azelastine Hcl | 144 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 143 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 142 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 142 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 134 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 20 |
| Tavaborole | Tavaborole | 126 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 122 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 19 |
| Buspirone Hcl | Buspirone Hcl | 116 | 16 |
| Propranolol Hcl | Propranolol Hcl | 113 | 19 |
| Brilinta | Ticagrelor | 111 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 111 | 20 |
| Aripiprazole | Aripiprazole | 109 | 15 |
| Zileuton Er | Zileuton | 109 | 15 |
| Methimazole | Methimazole | 108 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 106 | 20 |
| Dutasteride | Dutasteride | 106 | 15 |
| Nexium | Esomeprazole Magnesium | 106 | 11 |
| Levofloxacin | Levofloxacin | 105 | 84 |
| Metoclopramide Hcl | Metoclopramide Hcl | 105 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 85 |
| Pregabalin | Pregabalin | 104 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 103 | 16 |
| Farxiga | Dapagliflozin Propanediol | 99 | 19 |
| Primidone | Primidone | 99 | 11 |
| Benazepril Hcl | Benazepril Hcl | 97 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 97 | 14 |
| Synthroid | Levothyroxine Sodium | 96 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 95 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 94 | 16 |
| Lactulose | Lactulose | 92 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 14 |
| Bupropion Xl | Bupropion Hcl | 91 | 12 |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 90 | 15 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 90 | 15 |
| Spironolactone | Spironolactone | 90 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 11 |
| Ranolazine Er | Ranolazine | 89 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 87 | 15 |
| Cyclosporine | Cyclosporine | 86 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 65 |
| Trulicity | Dulaglutide | 82 | 12 |
| Lansoprazole | Lansoprazole | 79 | 13 |
| Entresto | Sacubitril/Valsartan | 78 | 15 |
| Fenofibrate | Fenofibrate,micronized | 77 | suppressed |
| Restasis | Cyclosporine | 76 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 75 | 11 |
| Methotrexate | Methotrexate Sodium | 74 | suppressed |
| Prolia | Denosumab | 73 | 48 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 12 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 70 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 70 | 18 |
| Latanoprost | Latanoprost | 70 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 19 |
| Crestor | Rosuvastatin Calcium | 66 | 12 |
| Fluconazole | Fluconazole | 64 | 31 |
| Single Use Swab | Alcohol Antiseptic Pads | 63 | 16 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 58 | suppressed |
| Irbesartan | Irbesartan | 57 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 54 | 30 |
| Ibu | Ibuprofen | 54 | 18 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 53 | suppressed |
| Dexilant | Dexlansoprazole | 53 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 53 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 53 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 51 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 50 | 15 |
| Loperamide | Loperamide Hcl | 49 | 18 |
| Lubiprostone | Lubiprostone | 49 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 49 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 49 | 12 |
| Cilostazol | Cilostazol | 48 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 11 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 46 | 20 |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 46 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 45 | suppressed |
| Ciclopirox | Ciclopirox | 45 | 11 |
| Gemtesa | Vibegron | 45 | 11 |
| Telmisartan | Telmisartan | 45 | suppressed |
| Acyclovir | Acyclovir | 44 | 14 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | suppressed |
| Nystatin | Nystatin | 44 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 41 | suppressed |
| Tirosint | Levothyroxine Sodium | 41 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 11 |
| Calcipotriene | Calcipotriene | 39 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 37 | suppressed |
| Ssd | Silver Sulfadiazine | 37 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 36 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 35 | 15 |
| Tacrolimus | Tacrolimus | 35 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 34 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 34 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Klor-Con 8 | Potassium Chloride | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 12 |
| Cephalexin | Cephalexin | 32 | 21 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Multaq | Dronedarone Hcl | 32 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 31 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 30 | suppressed |
| Proctozone-Hc | Hydrocortisone | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Benicar | Olmesartan Medoxomil | 29 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Uloric | Febuxostat | 29 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 28 | suppressed |
| Ubrelvy | Ubrogepant | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Calcipotriene-Betamethasone | Calcipotriene/Betamethasone | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 26 | 19 |
| Viberzi | Eluxadoline | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Anastrozole | Anastrozole | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Mitigare | Colchicine | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Calcium Acetate | Calcium Acetate | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 23 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Viibryd | Vilazodone Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Zetia | Ezetimibe | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Mupirocin | Mupirocin Calcium | 20 | suppressed |
| Mirabegron Er | Mirabegron | 19 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Tretinoin | Tretinoin | 17 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Desonide | Desonide | 16 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Permethrin | Permethrin | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 15 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 15 | suppressed |
| Plavix | Clopidogrel Bisulfate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Jublia | Efinaconazole | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Maxalt | Rizatriptan Benzoate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Albendazole | Albendazole | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amcinonide | Amcinonide | 12 | suppressed |
| Atelvia | Risedronate Sodium | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Flurbiprofen | Flurbiprofen | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lofena | Diclofenac Potassium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dymista | Azelastine/Fluticasone | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Paxil Cr | Paroxetine Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,687.16 · 67 records | ABBVIE INC. | ACCRUFER, BREZTRI, CAPLYTA, CREON, DUPIXENT, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PANCREAZE, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VIBERZI, ZAVZPRET, ZENPEP, ZEPBOUND | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error